Risk Assessment of Acute Myocardial Infarction and Stroke Associated with Long-Acting Muscarinic Antagonists, Alone or in Combination, versus Long-Acting beta2-Agonists

References

• GOLD. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2021 report). Global initiative for chronic obstructive lung disease; 2021. Available from: https://goldcopd.org/2021-gold-reports/. Accessed 23 March 2021.
   Google Scholar
• de Luise C, Lanes SF, Jacobsen J, et al. Cardiovascular and respiratory hospitalizations and mortality among users of tiotropium in Denmark. Eur J Epidemiol. 2007;22(4):267–272. doi:10.1007/s10654-007-9106-5
   PubMed Web of Science ®Google Scholar
• Jara M, Lanes SF, Wentworth C 3rd, et al. Comparative safety of long-acting inhaled bronchodilators: a cohort study using the UK THIN primary care database. Drug Saf. 2007;30(12):1151–1160. doi:10.2165/00002018-200730120-00007
   PubMed Web of Science ®Google Scholar
• Jara M, Wentworth C 3rd, Lanes S. A new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPD. BMJ Open. 2012;2(3):e000841. doi:10.1136/bmjopen-2012-000841
   PubMed Web of Science ®Google Scholar
• Macie C, Wooldrage K, Manfreda J, et al. Cardiovascular morbidity and the use of inhaled bronchodilators. Int J Chron Obstruct Pulmon Dis. 2008;3(1):163–169. doi:10.2147/COPD.S1516
   PubMedGoogle Scholar
• Ogale SS, Lee TA, Au DH, et al. Cardiovascular events associated with ipratropium bromide in COPD. Chest. 2010;137(1):13–19. doi:10.1378/chest.08-2367
   PubMed Web of Science ®Google Scholar
• Verhamme KM, Afonso AS, van Noord C, et al. Tiotropium handihaler and the risk of cardio- or cerebrovascular events and mortality in patients with COPD. Pulm Pharmacol Ther. 2012;25(1):19–26. doi:10.1016/j.pupt.2011.10.004
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300(12):1439–1450. doi:10.1001/jama.300.12.1439
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–1554. doi:10.1056/NEJMoa0805800
   PubMed Web of Science ®Google Scholar
• FDA. Early communication about an ongoing safety review of tiotropium (marketed as Spiriva handihaler); 2010. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm070651.htm. Accessed 27 August 2010.
   Google Scholar
• Singh S, Loke YK, Enright P, et al. Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications. Thorax. 2013;68(1):114–116. doi:10.1136/thoraxjnl-2011-201275
   PubMed Web of Science ®Google Scholar
• EMA. Summary of the risk management plan for Eklira genuair; 2021. Available from: https://www.ema.europa.eu/en/documents/rmp-summary /eklira-genuair-epar-risk-management-plan-summary_en.pdf. Accessed 6 December 2021.
   Google Scholar
• EMA. Summary of the risk management plan for Duaklir genuair; 2021. Available from: https://www.ema.europa.eu/en/documents/rmp-summary /duaklir-genuair-epar-risk-management-plan-summary_en. pdf. Accessed 6 December 2021.
   Google Scholar
• Rivero-Ferrer E, Olesen M, Plana E, et al. Characteristics of new users of aclidinium bromide, aclidinium/ formoterol, and other COPD medications in the United Kingdom, Denmark, and Germany. Clin Drug Investig. 2022;42(4):319–331. doi:10.1007/s40261-022-01120-2
   PubMed Web of Science ®Google Scholar
• Rebordosa C, Aguado J, Plana E, et al. Use of aclidinium did not increase the risk of death in a noninterventional cohort study in the clinical practice research datalink (CPRD), United Kingdom. Respir Med. 2019;152:37–43. doi:10.1016/j.rmed.2019.04.018
   PubMed Web of Science ®Google Scholar
• Rebordosa C, Plana E, Rubino A, et al. A cohort study to evaluate the risk of hospitalisation for congestive heart failure associated with the use of aclidinium and other chronic obstructive pulmonary disease medications in the UK clinical practice research datalink. Int J Chron Obstruct Pulmon Dis. 2021;16:1461–1475. doi:10.2147/COPD.S301624
   PubMed Web of Science ®Google Scholar
• Wolf A, Dedman D, Campbell J, et al. Data resource profile: clinical practice research datalink (CPRD) aurum. Int J Epidemiol. 2019;48(6):1740. doi:10.1093/ije/dyz034
   PubMed Web of Science ®Google Scholar
• Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ. 1991;302(6779):766–768. doi:10.1136/bmj.302.6779.766
   PubMed Web of Science ®Google Scholar
• Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy. 2003;23(5):686–689. doi:10.1592/phco.23.5.686.32205
   PubMed Web of Science ®Google Scholar
• Herrett E, Thomas SL, Schoonen WM, et al. Validation and validity of diagnoses in the general practice research database: a systematic review. Br J Clin Pharmacol. 2010;69(1):4–14. doi:10.1111/j.1365-2125.2009.03537.x
   PubMed Web of Science ®Google Scholar
• Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol. 2015;44(3):827–836. doi:10.1093/ije/dyv098
   PubMed Web of Science ®Google Scholar
• Jick SS, Hagberg KW, Persson R, et al. Quality and completeness of diagnoses recorded in the new CPRD Aurum database: evaluation of pulmonary embolism. Pharmacoepidemiol Drug Saf. 2020;29(9):1134–1140. doi:10.1002/pds.4996
   PubMed Web of Science ®Google Scholar
• Persson R, Vasilakis-Scaramozza C, Hagberg KW, et al. CPRD Aurum database: assessment of data quality and completeness of three important comorbidities. Pharmacoepidemiol Drug Saf. 2020;29(11):1456–1464. doi:10.1002/pds.5135
   PubMed Web of Science ®Google Scholar
• MHRA. Release notes: CPRD aurum March 2020. Medicines & Healthcare products Regulatory Agency; 2020.
   Google Scholar
• García Rodríguez LA, Varas-Lorenzo C, Maguire A, et al. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation. 2004;109(24):3000–3006. doi:10.1161/01.CIR.0000132491.96623.04
   PubMed Web of Science ®Google Scholar
• Ray WA, Varas-Lorenzo C, Chung CP, et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes. 2009;2(3):155–163. doi:10.1161/CIRCOUTCOMES.108.805689
   PubMed Web of Science ®Google Scholar
• Varas-Lorenzo C, Castellsague J, Stang MR, et al. The use of selective cyclooxygenase-2 inhibitors and the risk of acute myocardial infarction in Saskatchewan, Canada. Pharmacoepidemiol Drug Saf. 2009;18(11):1016–1025. doi:10.1002/pds.1815
   PubMed Web of Science ®Google Scholar
• Hammad TA, McAdams MA, Feight A, et al. Determining the predictive value of Read/OXMIS codes to identify incident acute myocardial infarction in the General practice research database. Pharmacoepidemiol Drug Saf. 2008;17(12):1197–1201. doi:10.1002/pds.1672
   PubMed Web of Science ®Google Scholar
• Arana A, Margulis AV, Varas-Lorenzo C, et al. Validation of cardiovascular outcomes and risk factors in the clinical practice research datalink in the United Kingdom. Pharmacoepidemiol Drug Saf. 2021;30(2):237–247. doi:10.1002/pds.5150
   PubMed Web of Science ®Google Scholar
• Jangaard N, Sarkisian L, Saaby L, et al. Incidence, frequency, and clinical characteristics of type 3 myocardial infarction in clinical practice. Am J Med. 2017;130(7):862.e869–862.e814. doi:10.1016/j.amjmed.2016.12.034
   PubMed Web of Science ®Google Scholar
• Andersohn F, Schade R, Suissa S, et al. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study. Stroke. 2006;37(7):1725–1730. doi:10.1161/01.STR.0000226642.55207.94
   PubMed Web of Science ®Google Scholar
• Arana A, Varas C, Gonzalez-Perez A, et al. Hormone therapy and cerebrovascular events: a population-based nested case-control study. Menopause. 2006;13(5):730–736. doi:10.1097/01.gme.0000233494.28335.71
   PubMed Web of Science ®Google Scholar
• Roumie CL, Mitchel E, Gideon PS, et al. Validation of ICD-9 codes with a high positive predictive value for incident strokes resulting in hospitalization using Medicaid health data. Pharmacoepidemiol Drug Saf. 2008;17(1):20–26. doi:10.1002/pds.1518
   PubMed Web of Science ®Google Scholar
• GOLD. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2016 report). Global initiative for chronic obstructive lung disease; 2016. Available from: http://goldcopd.org/gold-reports-2016/. Accessed 20 December 2016.
   Google Scholar
• Rothman K, Greenland S, Lash TL. Modern Epidemiology. 3rd ed. Lippincott Williams & Wilkins; 2008.
   Google Scholar
• Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev. 2019;10:ED000142. doi:10.1002/14651858.ED000142
   PubMed Web of Science ®Google Scholar
• Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med. 2014;33(7):1242–1258. doi:10.1002/sim.5984
   PubMed Web of Science ®Google Scholar
• Wasserstein RL, Lazar NA. The ASA statement on p-values: context, process, and purpose. Am Stat. 2016;70(2):129–133. doi:10.1080/00031305.2016.1154108
   Web of Science ®Google Scholar
• Greenland S, Senn SJ, Rothman KJ, et al. Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations. Eur J Epidemiol. 2016;31(4):337–350. doi:10.1007/s10654-016-0149-3
   PubMed Web of Science ®Google Scholar
• Amrhein V, Greenland S, McShane B. Scientists rise up against statistical significance. Nature. 2019;567(7748):305–307. doi:10.1038/d41586-019-00857-9
   PubMed Web of Science ®Google Scholar
• Rothman KJ, Lash TL. Precision and study size. In: Lash TL, VanderWeele TJ, Haneuse S, Rothman KJ, editors. Modern Epidemiology. 4th ed. Philadelphia, Pennsylvania: Wolters Kluwer; 2021.
   Google Scholar
• Barr RG, Bourbeau J, Camargo CA, et al. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax. 2006;61(10):854–862. doi:10.1136/thx.2006.063271
   PubMed Web of Science ®Google Scholar
• Celli B, Decramer M, Leimer I, et al. Cardiovascular safety of tiotropium in patients with COPD. Chest. 2010;137(1):20–30. doi:10.1378/chest.09-0011
   PubMed Web of Science ®Google Scholar
• Kesten S, Celli B, Decramer M, et al. Tiotropium handihaler in the treatment of COPD: a safety review. Int J Chron Obstruct Pulmon Dis. 2009;4:397–409. doi:10.2147/COPD.S4802
   PubMedGoogle Scholar
• Schmiedl S, Fischer R, Ibanez L, et al. Tiotropium Respimat® vs. HandiHaler®: real-life usage and TIOSPIR trial generalizability. Br J Clin Pharmacol. 2016;81(2):379–388. doi:10.1111/bcp.12808
   PubMed Web of Science ®Google Scholar
• Walker S, Fingleton J, Weatherall M, et al. Limited generalisability of UPLIFT findings to clinical practice. Thorax. 2013;68(11):1066–1067. doi:10.1136/thoraxjnl-2013-203724
   PubMed Web of Science ®Google Scholar
• Wise RA, Chapman KR, Scirica BM, et al. Effect of aclidinium bromide on major cardiovascular events and exacerbations in high-risk patients with chronic obstructive pulmonary disease: the ASCENT-COPD randomized clinical trial. JAMA. 2019;321(17):1693–1701. doi:10.1001/jama.2019.4973
   PubMed Web of Science ®Google Scholar